Mumbai, Jan. 13 -- Sentynl Therapeutics Inc. (Sentynl), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences (Zydus Group), announced that the U.S. Food and Drug Administration has approved ZYCUBO(R) (copper histidinate) for the treatment of Menkes disease in pediatric patients. This is the first and only treatment approved for Menkes disease, a rare and fatal genetic condition, in the United States. ZYCUBO(R) is not indicated for the treatment of Occipital Horn Syndrome.

Published by HT Digital Content Services with permission from Capital Market....